Intracellular News and Research

RSS

Scientists discover cholesterol moves far slower within and between cells

Neutrons have shown the movement of cholesterol between and within cells takes far longer than previously thought. Findings could impact the treatment of a range of diseases linked to abnormal rates of cholesterol transfer.

19 Jul 2011

Scientists identify new inherited form of Parkinson's disease

Scientists at the Helmholtz Zentrum München and the Technische Universität München working in cooperation with the Medical University of Vienna have identified a mutation associated with a inherited form of late-onset Parkinson's disease.

19 Jul 2011

Alnylam seeks CTA clearance to initiate ALN-PCS Phase I clinical trial for severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I clinical trial with ALN-PCS, an RNAi therapeutic for the treatment of severe hypercholesterolemia.

11 Jul 2011

New technique explores how cells react to rapidly changing patterns of chemoattractants

Many cell types in higher organisms are capable of implementing directed motion in response to the presence of certain chemical attractants in their vicinity. A team led by Dr. Doris Heinrich of the Faculty of Physics and the Center for NanoScience (CeNS) at Ludwig-Maximilians-Universit-t (LMU) in Munich has developed a novel technique to expose an ensemble of living cells to rapidly varying concentrations of chemoattractants.

6 Jul 2011

Acetylon to advance ACY-1215 drug candidate with $27M Series B Preferred equity investment round of financing

Acetylon Pharmaceuticals, Inc. announced today that it has completed a $27 million Series B Preferred equity investment round of financing.

29 Jun 2011

Biolauncher, Isogenica and Cresset enter joint venture to develop drug discovery platform

Isogenica Ltd today announced a collaborative joint venture with Biolauncher Ltd and Cresset Biomolecular Discovery Ltd to develop an innovative end-to-end therapeutic discovery platform.

28 Jun 2011

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Sanofi-aventis announced today that Health Canada has granted market authorization for Jevtana injection in combination with prednisone for the treatment of patients with metastatic castration resistant prostate cancer, previously treated with a docetaxel-containing treatment regimen.

24 Jun 2011

UC Riverside research could lead to novel therapeutics for epileptic seizures

Researchers at the University of California, Riverside have made a discovery in the lab that could help drug manufacturers develop new antiepileptic drugs and explore novel strategies for treating seizures associated with epilepsy - a disease affecting about two million Americans.

22 Jun 2011

New insight into progressive supranuclear palsy

There are new genetic clues on risk factors and biological causes of a rare neurodegenerative disease called progressive supranuclear palsy (PSP), according to a new study from an international genetics team led by researchers from the Perelman School of Medicine at the University of Pennsylvania.

20 Jun 2011

Oncogene Aurora A may contribute to polycystic kidney disease

The Aurora A kinase may contribute to polycystic kidney disease (PKD) by inactivating a key calcium channel in kidney cells, according to a study in the June 13 issue of The Journal of Cell Biology.

13 Jun 2011

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

2 Jun 2011

Positive data from Augurex's RA biomarker blood test, novel drug target presented at EULAR conference

Augurex Life Sciences Corp. today reported that in London at the European League Against Rheumatism Conference, leading arthritis researchers presented important data on Augurex's rheumatoid arthritis biomarker blood test and novel drug target.

30 May 2011

Stem cell pluripotency depends on E-cadherin molecule

Researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have discovered what enables embryonic stem cells to differentiate into diverse cell types and thus to be pluripotent. This pluripotency depends on a specific molecule - E-cadherin - hitherto primarily known for its role in mediating cell-cell adhesion as a kind of "intracellular glue".

27 May 2011

A new gene expression analysis technique on a single molecule sequencer

A new gene expression technique adapted for single molecule sequencing has enabled researchers at the RIKEN Omics Science Center (OSC) to accurately and quantitatively measure gene expression levels using only 100 nanograms of total RNA. The technique, which pairs RIKEN's Cap Analysis of Gene Expression (CAGE) protocol with the Helicos(R) Genetic Analysis System developed by Helicos BioSciences Corporation, opens the door to the detailed analysis of gene expression networks and rare cell populations. In recent years, next-generation DNA sequencers have produced an increasingly detailed picture of how genes are expressed at the molecular level. The transcriptional output of these genes - the RNA copies produced from DNA - has revealed a richness of complexity in transcript structure and function, providing insights into the molecular-level properties of cancers and other diseases.

19 May 2011

New insight into skin hardening syndromes

Researchers from Boston University School of Medicine have discovered new details about the underlying mechanisms of skin hardening syndromes.

18 May 2011

New study sheds light on origins of myeloid leukemia

A new study by the NYU Cancer Institute, an NCI-designated cancer center, sheds light on the origins of myeloid leukemia, a type of blood cancer that affects children and adults.

13 May 2011

Biocept's paper describes identification of different CTC phenotypes in cancer patients

Biocept, Inc., a privately-held laboratory testing company focused on the detection, enumeration and analysis of circulating tumor cells (CTCs) in cancer patients, today announced the publication of a paper describing the identification of different CTC phenotypes using its proprietary Cell Enrichment and Extraction platform.

12 May 2011

biocrea and Pfizer jointly presented details on novel PDE10 inhibitors

biocrea, a biopharmaceutical company focusing on novel treatments for disorders of the central nervous system (CNS), today reported details on the design and synthesis of novel, brain-penetrating phosphodiesterase-10 (PDE10) inhibitors developed in collaboration with Pfizer Inc. (NYSE: PFE). The data were featured in joint presentations1 with Pfizer at the recent 241st ACS National Meeting & Exposition, an event organized by the American Chemical Society (ACS).

10 May 2011

Scientists reveal nerve cells' navigation system

Johns Hopkins scientists have discovered how two closely related proteins guide projections from nerve cells with exquisite accuracy, alternately attracting and repelling these axons as they navigate the most miniscule and frenetic niches of the nervous system to make remarkably precise connections.

9 May 2011

Cempra to present solithromycin Phase 1 study data at ECCMID/ICC meeting

Cempra Pharmaceuticals, a developer of differentiated antibiotics, today announced an oral presentation showing that intravenous (IV) solithromycin demonstrates excellent tolerability and a favorable pharmacokinetic profile at IV doses up to 800 mg.

7 May 2011